{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:31:09Z","timestamp":1794047469127,"version":"4.8.0"},"reference-count":39,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"8","license":[{"start":{"date-parts":[[2024,2,22]],"date-time":"2024-02-22T00:00:00Z","timestamp":1708560000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>Multiple myeloma (MM) remains incurable due to disease relapse and drug resistance. Notch signals from the tumor microenvironment (TME) confer chemoresistance, but the cellular and molecular mechanisms are not entirely understood. Using clinical and transcriptomic datasets, we found that NOTCH3 is upregulated in CD138+ cells from newly diagnosed MM (NDMM) patients compared to healthy individuals and increased in progression\/relapsed MM (PRMM) patients. Further, NDMM patients with high NOTCH3 expression exhibited worse responses to bortezomib (BOR)-based therapies. Cells of the TME, including osteocytes, upregulated NOTCH3 in MM cells and protected them from apoptosis induced by BOR. NOTCH3 activation (NOTCH3OE) in MM cells decreased BOR anti-MM efficacy and its ability to improve survival in in vivo myeloma models. Molecular analyses revealed that NDMM and PRMM patients with high NOTCH3 exhibit CXCL12 upregulation. TME cells upregulated CXCL12 and activated the CXCR4 pathway in MM cells in a NOTCH3-dependent manner. Moreover, genetic or pharmacologic inhibition of CXCL12 in NOTCH3OE MM cells restored sensitivity to BOR regimes in vitro and in human bones bearing NOTCH3OE MM tumors cultured ex vivo. Our clinical and preclinical data unravel a novel NOTCH3-CXCL12 pro-survival signaling axis in the TME and suggest that osteocytes transmit chemoresistance signals to MM cells.<\/jats:p>","DOI":"10.3324\/haematol.2023.284443","type":"journal-article","created":{"date-parts":[[2024,2,22]],"date-time":"2024-02-22T04:28:43Z","timestamp":1708576123000},"page":"2606-2618","source":"Crossref","is-referenced-by-count":11,"title":["A NOTCH3-CXCL12-driven myeloma-tumor niche signaling axis promotes chemoresistance in multiple myeloma"],"prefix":"10.3324","volume":"109","author":[{"given":"Hayley M.","family":"Sabol","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cody","family":"Ashby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manish","family":"Adhikari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aric","family":"Anloague","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Japneet","family":"Kaur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharmin","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samrat Roy","family":"Choudhury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina","family":"Schinke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michela","family":"Palmieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. Lowry","family":"Barnes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Ambrogini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Intawat","family":"Nookaew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesus","family":"Delgado-Calle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2024,2,22]]},"reference":[{"key":"64702","doi-asserted-by":"crossref","unstructured":"Rajkumar SV, Kumar S. Multiple myeloma current treatment algorithms. Blood Cancer J. 2020; 10(9):94.","DOI":"10.1038\/s41408-020-00359-2"},{"key":"64703","doi-asserted-by":"crossref","unstructured":"Maiso P, Mogoll\u00f3n P, Ocio EM, Garayoa M. Bone marrow mesenchymal stromal cells in multiple myeloma: their role as active contributors to myeloma progression. Cancers (Basel). 2021; 13(11):2542.","DOI":"10.3390\/cancers13112542"},{"key":"64704","doi-asserted-by":"crossref","unstructured":"Ria R, Vacca A. Bone marrow stromal cells-induced drug resistance in multiple myeloma. Int J Mol Sci. 2020; 21(2):613.","DOI":"10.3390\/ijms21020613"},{"key":"64705","doi-asserted-by":"crossref","unstructured":"Nefedova Y, Landowski TH, Dalton WS. Bone marrow stromal-derived soluble factors and direct cell contact contribute to de novo drug resistance of myeloma cells by distinct mechanisms. Leukemia. 2003; 17(6):1175-1182.","DOI":"10.1038\/sj.leu.2402924"},{"key":"64706","doi-asserted-by":"crossref","unstructured":"Colombo M, Galletti S, Garavelli S. Notch signaling deregulation in multiple myeloma: a rational molecular target. Oncotarget. 2015; 6(29):26826-26840.","DOI":"10.18632\/oncotarget.5025"},{"key":"64707","doi-asserted-by":"crossref","unstructured":"Nefedova Y, Sullivan DM, Bolick SC, Dalton WS, Gabrilovich DI. Inhibition of Notch signaling induces apoptosis of myeloma cells and enhances sensitivity to chemotherapy. Blood. 2008; 111(4):2220-2229.","DOI":"10.1182\/blood-2007-07-102632"},{"key":"64708","doi-asserted-by":"crossref","unstructured":"Wang Z, Li Y, Ahmad A. Targeting Notch signaling pathway to overcome drug resistance for cancer therapy. Biochim Biophys Acta. 2010; 1806(2):258-267.","DOI":"10.1016\/j.bbcan.2010.06.001"},{"key":"64709","doi-asserted-by":"crossref","unstructured":"Colombo M, Garavelli S, Mazzola M. Multiple myeloma exploits Jagged1 and Jagged2 to promote intrinsic and bone marrow-dependent drug resistance. Haematologica. 2020; 105(7):1925-1936.","DOI":"10.3324\/haematol.2019.221077"},{"key":"64710","doi-asserted-by":"crossref","unstructured":"Sabol HM, Amorim T, Ashby C. Notch3 signaling between myeloma cells and osteocytes in the tumor niche promotes tumor growth and bone destruction. Neoplasia. 2022; 28:100785.","DOI":"10.1016\/j.neo.2022.100785"},{"key":"64711","doi-asserted-by":"crossref","unstructured":"Delgado-Calle J, Bellido T. The osteocyte as a signaling cell. Physiol Rev. 2022; 102(1):379-410.","DOI":"10.1152\/physrev.00043.2020"},{"key":"64712","doi-asserted-by":"crossref","unstructured":"Choudhury SR, Ashby C, Tytarenko R. The functional epigenetic landscape of aberrant gene expression in molecular subgroups of newly diagnosed multiple myeloma. J Hematol Oncol. 2020; 13(1):108.","DOI":"10.1186\/s13045-020-00933-y"},{"key":"64713","doi-asserted-by":"crossref","unstructured":"Delgado-Calle J, Anderson J, Cregor MD. Bidirectional Notch signaling and osteocyte-derived factors in the bone marrow microenvironment promote tumor cell proliferation and bone destruction in multiple myeloma. Cancer Res. 2016; 76(5):1089-1100.","DOI":"10.1158\/0008-5472.CAN-15-1703"},{"key":"64714","doi-asserted-by":"crossref","unstructured":"Sabol HM, Ferrari AJ, Adhikari M. Targeting Notch inhibitors to the myeloma bone marrow niche decreases tumor growth and bone destruction without gut toxicity. Cancer Res. 2021; 81(19):5102-5114.","DOI":"10.1158\/0008-5472.CAN-21-0524"},{"key":"64715","doi-asserted-by":"crossref","unstructured":"Delgado-Calle J, Anderson J, Cregor MD. Genetic deletion of Sost or pharmacological inhibition of sclerostin prevent multiple myeloma-induced bone disease without affecting tumor growth. Leukemia. 2017; 31(12):2686-2694.","DOI":"10.1038\/leu.2017.152"},{"key":"64716","doi-asserted-by":"crossref","unstructured":"Mulligan G, Mitsiades C, Bryant B. Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib. Blood. 2007; 109(8):3177-3188.","DOI":"10.1182\/blood-2006-09-044974"},{"key":"64717","doi-asserted-by":"crossref","unstructured":"Bellido T, Delgado-Calle J. Ex vivo organ cultures as models to study bone biology. JBMR Plus. 2020; 4(3):10.","DOI":"10.1002\/jbm4.10345"},{"key":"64718","doi-asserted-by":"crossref","unstructured":"Waldschmidt JM, Simon A, Wider D. CXCL12 and CXCR7 are relevant targets to reverse cell adhesion-mediated drug resistance in multiple myeloma. Br J Haematol. 2017; 179(1):36-49.","DOI":"10.1111\/bjh.14807"},{"key":"64719","doi-asserted-by":"crossref","unstructured":"Bouyssou JM, Ghobrial IM, Roccaro AM. Targeting SDF-1 in multiple myeloma tumor microenvironment. Cancer Lett. 2016; 380(1):315-318.","DOI":"10.1016\/j.canlet.2015.11.028"},{"key":"64720","doi-asserted-by":"crossref","unstructured":"Cohen YC, Zada M, Wang SY. Identification of resistance pathways and therapeutic targets in relapsed multiple myeloma patients through single-cell sequencing. Nat Med. 2021; 27(3):491-503.","DOI":"10.1038\/s41591-021-01232-w"},{"key":"64721","doi-asserted-by":"crossref","unstructured":"Ullah TR. The role of CXCR4 in multiple myeloma: cells\u2019 journey from bone marrow to beyond. J Bone Oncol. 2019; 17:100253.","DOI":"10.1016\/j.jbo.2019.100253"},{"key":"64722","doi-asserted-by":"crossref","unstructured":"Ren Z, Lantermans H, Kuil A. The CXCL12gamma chemokine immobilized by heparan sulfate on stromal niche cells controls adhesion and mediates drug resistance in multiple myeloma. J Hematol Oncol. 2021; 14(1):11.","DOI":"10.1186\/s13045-021-01031-3"},{"key":"64723","doi-asserted-by":"crossref","unstructured":"Anloague A, Delgado-Calle J. Osteocytes: new kids on the block for cancer in bone therapy. Cancers (Basel). 2023; 15(9):2645.","DOI":"10.3390\/cancers15092645"},{"key":"64724","doi-asserted-by":"crossref","unstructured":"Atkinson EG, Delgado-Calle J. The emerging role of osteocytes in cancer in bone. JBMR Plus. 2019; 3(3):e10186.","DOI":"10.1002\/jbm4.10186"},{"key":"64725","doi-asserted-by":"crossref","unstructured":"Pin F, Prideaux M, Bonewald LF, Bonetto A. Osteocytes and cancer. Curr Osteoporos Rep. 2021; 19(6):616-625.","DOI":"10.1007\/s11914-021-00712-9"},{"key":"64726","doi-asserted-by":"crossref","unstructured":"Cheng F, Wang Z, You G, Liu Y, He J, Yang J. Osteocyte-derived exosomes confer multiple myeloma resistance to chemotherapy through acquisition of cancer stem cell-like features. Leukemia. 2023; 37(6):1392-1396.","DOI":"10.1038\/s41375-023-01896-y"},{"key":"64727","doi-asserted-by":"crossref","unstructured":"Fairfield H, Falank C, Avery L, Reagan MR. Multiple myeloma in the marrow: pathogenesis and treatments. Ann N Y Acad Sci. 2016; 1364(1):32-51.","DOI":"10.1111\/nyas.13038"},{"key":"64728","doi-asserted-by":"crossref","unstructured":"Colombo M, Platonova N, Giannandrea D, Palano MT, Basile A, Chiaramonte R. Re-establishing apoptosis competence in bone associated cancers via communicative reprogramming induced through Notch signaling inhibition. Front Pharmacol. 2019; 10:145.","DOI":"10.3389\/fphar.2019.00145"},{"key":"64729","doi-asserted-by":"crossref","unstructured":"Nefedova Y, Cheng P, Alsina M, Dalton WS, Gabrilovich DI. Involvement of Notch-1 signaling in bone marrow stromamediated de novo drug resistance of myeloma and other malignant lymphoid cell lines. Blood. 2004; 103(9):3503-3510.","DOI":"10.1182\/blood-2003-07-2340"},{"key":"64730","doi-asserted-by":"crossref","unstructured":"Muguruma Y, Yahata T, Warita T. Jagged1-induced Notch activation contributes to the acquisition of bortezomib resistance in myeloma cells. Blood Cancer J. 2017; 7(12):650.","DOI":"10.1038\/s41408-017-0001-3"},{"key":"64731","doi-asserted-by":"crossref","unstructured":"Mirandola L, Apicella L, Colombo M. Anti-Notch treatment prevents multiple myeloma cells localization to the bone marrow via the chemokine system CXCR4\/SDF-1. Leukemia. 2013; 27(7):1558-1566.","DOI":"10.1038\/leu.2013.27"},{"key":"64732","doi-asserted-by":"crossref","unstructured":"Di Marzo L, Desantis V, Solimando AG. Microenvironment drug resistance in multiple myeloma: emerging new players. Oncotarget. 2016; 7(37):60698-60711.","DOI":"10.18632\/oncotarget.10849"},{"key":"64733","doi-asserted-by":"crossref","unstructured":"Azab AK, Runnels JM, Pitsillides C. CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy. Blood. 2009; 113(18):4341-4351.","DOI":"10.1182\/blood-2008-10-186668"},{"key":"64734","doi-asserted-by":"crossref","unstructured":"Raje N, Terpos E, Willenbacher W. Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, doubledummy, randomised, controlled, phase 3 study. Lancet Oncol. 2018; 19(3):370-381.","DOI":"10.1016\/S1470-2045(18)30072-X"},{"key":"64735","doi-asserted-by":"crossref","unstructured":"Silbermann R, Roodman GD. Myeloma bone disease: pathophysiology and management. J Bone Oncol. 2013; 2(2):59-69.","DOI":"10.1016\/j.jbo.2013.04.001"},{"key":"64736","doi-asserted-by":"crossref","unstructured":"Varga J, Nicolas A, Petrocelli V. AKT-dependent NOTCH3 activation drives tumor progression in a model of mesenchymal colorectal cancer. J Exp Med. 2020; 217(10):e201921515.","DOI":"10.1084\/jem.20191515"},{"key":"64737","doi-asserted-by":"crossref","unstructured":"Choy L, Hagenbeek TJ, Solon M. Constitutive NOTCH3 signaling promotes the growth of basal breast cancers. Cancer Res. 2017; 77(6):1439-1452.","DOI":"10.1158\/0008-5472.CAN-16-1022"},{"key":"64738","doi-asserted-by":"crossref","unstructured":"Yu J, Siebel CW, Schilling L, Canalis E. An antibody to Notch3 reverses the skeletal phenotype of lateral meningocele syndrome in male mice. J Cell Physiol. 2020; 235(1):210-220.","DOI":"10.1002\/jcp.28960"},{"key":"64739","doi-asserted-by":"crossref","unstructured":"Golde TE, Koo EH, Felsenstein KM, Osborne BA, Miele L. \u03b3-Secretase inhibitors and modulators. Biochim Biophys Acta. 2013; 1828(12):2898-2907.","DOI":"10.1016\/j.bbamem.2013.06.005"},{"key":"64740","doi-asserted-by":"crossref","unstructured":"Ghobrial IM, Liu CJ, Zavidij O. Phase I\/II trial of the CXCR4 inhibitor plerixafor in combination with bortezomib as a chemosensitization strategy in relapsed\/refractory multiple myeloma. Am J Hematol. 2019; 94(11):1244-1253.","DOI":"10.1002\/ajh.25627"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2023.284443\/76625","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2023.284443\/77352","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/11468\/76625","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:05:47Z","timestamp":1794045947000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/haematol.2023.284443"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,22]]},"references-count":39,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2024,8,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2023.284443","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2,22]]}}}